Evidence map›Paper›PMID 34585972›Full record

ArticleMicrobiology spectrum2021

Risk Factors for Relapse in Acute Bacterial Prostatitis: the Impact of Antibiotic Regimens.

Ester Marquez-Algaba, Carles Pigrau, Pau Bosch-Nicolau, Belen Viñado, Judit Serra-Pladevall, Benito Almirante, Joaquín Burgos

Open access · goldAbstract read
In one paragraph

Article in Microbiology spectrum, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.1field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 14 citations in OpenAlex.

  1. Review
  2. Clinical Outcomes ofAntibiotics (Basel, Switzerland) · 2025
    Article
  3. Review
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Ester Marquez-AlgabaDepartment of Infectious Diseases, Vall d'Hebron Institut de Recerca (VHIR), Universitat Autonoma de Barcelona, Hospital Universitari Vall d'Hebron, Barcelona, Spain.ORCID 0000-0002-9824-0138
Carles PigrauDepartment of Infectious Diseases, Vall d'Hebron Institut de Recerca (VHIR), Universitat Autonoma de Barcelona, Hospital Universitari Vall d'Hebron, Barcelona, Spain.
Pau Bosch-NicolauDepartment of Infectious Diseases, Vall d'Hebron Institut de Recerca (VHIR), Universitat Autonoma de Barcelona, Hospital Universitari Vall d'Hebron, Barcelona, Spain.
Belen ViñadoDepartment of Microbiology, Hospital Universitari Vall d'Hebron, Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain.
Judit Serra-PladevallDepartment of Microbiology, Hospital Universitari Vall d'Hebron, Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain.
Benito AlmiranteDepartment of Infectious Diseases, Vall d'Hebron Institut de Recerca (VHIR), Universitat Autonoma de Barcelona, Hospital Universitari Vall d'Hebron, Barcelona, Spain.
Joaquín BurgosDepartment of Infectious Diseases, Vall d'Hebron Institut de Recerca (VHIR), Universitat Autonoma de Barcelona, Hospital Universitari Vall d'Hebron, Barcelona, Spain.
Universitat Autònoma de Barcelona · ESRed Espanola de Investigacion en Patologia Infecciosa · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The aim of the study was to analyze the risk factors for relapse in patients with acute bacterial prostatitis (ABP), focusing on the impact of different antibiotic regimens. We conducted an observational study of all patients diagnosed with ABP (irritative and/or obstructive urinary symptoms, temperature of >37.8°C, and the presence of bacteriuria in urine culture, in the absence of data suggesting pyelonephritis) from January 2017 to December 2018. The main outcome was relapse. We performed a multivariate analysis to identify the risk factors associated with relapse. A propensity score with inverse weighting was applied to attenuate antibiotic selection bias. We included 410 patients. The mean age was 68 years; 28.8% had diabetes mellitus, and 61.1% benign prostatic hyperplasia. The most common isolated bacteria were Escherichia coli (62.4%) and Klebsiella spp. (10%). The overall resistance rate was 39.5% to quinolones. The mortality rate was 1.2%, and the relapse rate was 6.3%. The only independent risk factor for relapse was inadequate antibiotic therapy (odds ratio [OR] 12.3; 95% confidence interval [95% CI], 3.5 to 43.1). When the antibiotic was modified according to the susceptibility pattern, the rates of relapse were 1.8% in those treated with ciprofloxacin, 3.6% with intravenous beta-lactam, 9.3% with co-trimoxazole, and 9.8% with oral (p.o.) beta-lactam (

Indexed as

AdultAgedAged, 80 and overAnti-Bacterial AgentsBacteriuriabeta-LactamsChronic DiseaseDrug Resistance, BacterialFemaleHumansMaleMiddle AgedProstatitisPyelonephritisQuinolonesRecurrenceAnti-Bacterial Agentsbeta-LactamsQuinolonesTrimethoprim, Sulfamethoxazole Drug Combinationacute bacterial prostatitisantibiotic resistancebeta-lactamsco-trimoxazolequinolonesrelapse

Identifiers

PMID34585972
PMCPMC8557861
OpenAlexW3202233765

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.